Meghani et al.,, using material from BRCA1/2-deficient ovarian carcinoma patients, patient-derived lines, and an in vivo BRCA2-mutated mouse model, identified a microRNA, miR-493-5p, that induced platinum/PARPi resistance in BRCA2-mutated carcinomas [88]. This evidence concerns the gene BRCA1 and ovarian carcinoma.